FSTX News and Press, F-star Therapeutics Inc Com From 05/10/21

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today t...

Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...

Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...

ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme  (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...

F-star Therapeutics (FSTX) trades 18.8% down premarket after pricing its earlier announced underwritten public offering of 9.28M shares at $7/share; underwriters granted 30-day option to purchase up to 1.39M additional shares.Offer expected to close on or about May 11...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to trans...

F-star Therapeutics (FSTX) announces that it has commenced an underwritten public offering of shares.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% shares.F-star intends to use net proceeds, together with its existing cash and cash equivalents, for ...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to trans...

SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- F-star The...

Gainers: Clover Health Investments (CLOV) +20%, Harrow Health (HROW) +12%, Brooklyn ImmunoTherapeutics (BTX) +8%, Evoke Pharma (EVOK) +8%, F-star Therapeutics (FSTX) +7%.Losers: Editas Medicine (EDIT) -15%, Timber Pharmaceuticals (TMBR) -...